Apomorphine a dopamine receptor agonist was given subcutaneously to 57 levodopa treated parkinsonian patients with refractory off-period disabilities for a median period of 16 months. In 30 given intermittent suprathreshold injections the mean number of hours spent in a disabling off state fell from 6-9 to 2-9. Similar benefit was observed in 21 patients receiving continuous infusions with additional boluses on demand by mini-pump (mean reduction of hours off from 9-9 to 4-5). Twelve patients have been treated for over two years without tachyphylaxis or loss of response. The incidence of neuropsychiatric sideeffects has been low (7%). Six patients failed to show a sustained worthwhile response; severe disabilities during "on"9 periods being the major problem. Subcutaneous apomorphine is proposed as an effective treatment for patients with incapacitating "off" period disabilities refractory to oral medication and should be considered before experimental implantation procedures.
The incidence of disabling "on-oft" fluctuations increases with the duration of levodopa treatment and after ten years of sustained therapy most patients are affected.' For the majority treatment is difficult. The use of selegiline,23 partial substitution of levodopa by orally administered dopamine agonists4 and controlled-release levodopa preparations56 may temporarily extend "on" periods in some patients. Subcutaneous apomorphine, a directly acting dopamine agonist with affinity for both D 1 and D2 receptors, rapidly and consistently reverses the "off" period motor deficit. 78 We have previously described our initial experience with either continuous subcutaneous infusion or intermittent parenteral injection of apomorphine in 19 patients with severe "on-off" fluctuations.9 Eleven patients treated with subcutaneous infusion showed marked and sustained improvement; mean "off' hours per day were reduced from 10-1 to 3-8 and during the remaining "off" periods the mean disability score fell. Comparable results were obtained in eight patients with less severe disabilities given intermittent injections. Other reports have supported these observations. 112 We report our further experience in 57 patients with disabling levodopa related motor oscillations treated with subcutaneous apomorphine for periods up to 32 months.
The effects of apomorphine in patients with additional disabilities including biphasic dyskinesias, urinary dysfunction and "oft" period pain, dystonia, dyspnoea, anismus and belching have also been studied.
Patients and methods
Fifty seven levodopa treated patients with idiopathic Parkinson's disease were treated with apomorphine. In all cases disabling "onoff" fluctuations in motor performance remained despite attempts to improve control by redistribution of levodopa doses, concurrent use of dopamine agonists (57%) or selegiline (91 %), controlled release levodopa preparations (10%), and dietary protein restriction.
Their mean age was 58-9 years and disease duration 15 9 years. All patients were admitted to hospital for pre-treatment assessment and instruction in the use of subcutaneous injection or infusion techniques.
It was first established that patients had incapacitating fluctuations, despite optimally timed doses of levodopa, by both clinical observation and the use of self-scoring patient diaries. If necessary, oral challenges of levodopa after withdrawal of overnight medication was followed by assessment to determine the duration of motor response and quality of the "on" period.
Patients with significant cardiovascular, hepatic or renal pathology were excluded. NQ patients with current evidence of neuropsychiatric disturbance or dementia were included. Routine haematological and bi9-chemical indices were measured before therapy and thereafter at monthly intervals.
To avoid side-effects such as nausea, vomiting and postural hypotension, domperidone,13 a peripherally acting dopamine receptor Figure 1 The 'Penject' multiple injection device.
antagonist (20 mg orally) was given two hours before a test dose of apomophine. One mg of apomorphine (apomorphine HCl 10 mg/ml) was given subcutaneously during an "off" period, provoked by witholding levodopa medication. Diary records in the first eight patients treated, showed a mean reduction in "off" hours from 6-0 to 2-7 (p < 0-01) shortly after starting apomorphine; at one year mean "off" hours was 3-2. The 30 patients who remained on long-term treatment were reviewed after a mean duration of 13 5 months (range 5-26). Total daily "off" hours fell from 6-9 before treatment to 2 9 (p < 0 02); this improvement has been maintained.
Individual injections of apomorphine, given during "off' periods, produced benefit subjectively equivalent to the levodopa "on" period motor response. Larger doses increased duration of action and the severity of dyskinesias. Some patients would vary the dose depending upon the severity of an "off" period. Dose failure was reported more often later in the day. This appeared to correlate with the increased 
B Dyskinesias
Most patients had only moderately severe drug-induced involuntary movements during "on" periods. There were however four with disabling biphasic dyskinesias and nine with severe inter-dose involuntary movements. Biphasic dyskinesias initially responded favourably to both single injections and continuous infusions of apomorphine, but improvement was maintained for at most a few days after which dyskinesias broke through and eventually occurred almost continually during "on" periods. In five of the patients with severe inter-dose chorea it was possible to reduce the frequency and severity of drug-induced dyskinesia, by reducing the frequency and size of levodopa doses and treating the resulting increase in "off" periods with appropriately timed doses of apomorphine. However, worthwhile improvement was not always possible particularly when this feature alone had been the main incapacity. In two patients in whom it was not possible to reduce dyskinesia severity they elected to continue occasional apomorphine injections to treat particularly severe "off" episodes, when conversion to a dyskinetic state was felt to be preferable. One, of four treated, with biphasic dyskinesias remained on apomorphine, using single injections approximately once per day to provide a rapid and reliable "on" usually in the late afternoon when their response to levodopa had been unpredictable.
C Positive "off' period phenomena Injections of apomorphine were useful in terminating other parkinsonian disabilities. Two patients with "off" period functional bladder outlet obstruction'4 benefited from appropriately timed injections; three with parkinsonian obstructive defaecation (anismus)'5 16 were able to empty their bowels more effectively; three with severe "off" period limb and pelvic pain and two with early morning dystonia responded promptly; two suffering from distressing paroxysmal belching during "off" periods'7 resistant to oral levodopa found that appropriately timed doses almost completely suppressed the symptom; and one man with "off" period hallucinations responded well to intermittent injection. We also gave apomorphine infusions to two patients with advanced disease who had critically deteriorated; in one precipitated by a chest infection and in the other following a profound depressive illness when the patient had discontinued levodopa. Both were in extremis with generalised rigidity, akinesia and fever despite maximal tolerated doses of levodopa. (ii) Neuropsychiatric Visual hallucinations and confusion occurred in three patients, on continuous apomorphine infusions. After six months of treatment, a 60 year old woman complained of seeing small worms on her food and in her home, these symptoms resolved when her apomorphine was reduced. A 67 year old man experienced visual pseudo-hallucinations which had previously occurred when taking levodopa and a 62 year old man, given a trial of apomorphine, developed paranoid ideas and complained of seeing animals and people. His mental state returned to normal on withdrawal oftreatment. Also a 67 year old woman with severe disability, who had responded favourably for over six months on continuous infusion, became gradually more disabled by hypotonia during "on" periods. She then became increasingly paranoid and withdrawn, and later mute. Both levodopa and apomorphine were withdrawn in turn without improvement.
Three patients with histories of psychosis on other antiparkinsonian medication were not affected. (iii) Other symptoms Most patients initially experienced mild drowsiness usually accompanied by yawning but this persisted only in two. Many reported occasional nausea in relation to apomorphine injections and postural hypotension was encountered on two occasions, this was usually attributable to the omission of domperidone.
A 62 year old man consistently noticed a generalised unpleasant sensation following apomorphine injections which he had not experienced after doses of levodopa producing a comparable benefit. Two patients described rhinorrhoea and increased lacrimation shortly after injections; one had previously noted the same phenomena after levodopa.
A 58 year old man, complained of reduced facial hair growth and loss of libido after starting treatment with intermittent injections of apomorphine. On the other hand, a 64 year old man became embarrassingly hyperlibidinous.
An overdose of apomorphine occurred in a 62 year old man on a continuous infusion. His wife accidentally injected subcutaneously about 25 mg of apomorphine. After three minutes he felt faint, nauseated, lost consciousness and recovered within 20 minutes. He was then found to be alert with a pulse rate of 40/minute and his supine blood pressure was 90/50 mm Hg. He recovered completely within an hour. One patient broke a needle during injection and the fragment remains in the subcutaneous tissue.
(iv) Laboratory investigations Peripheral blood eosinophilia of up to 10 per cent occurred shortly after starting therapy in all patients treated by continuous infusion; this returned to normal in about half of the patients treated for over one year. Other haematological indices, including plasma urea and creatinine concentrations remained normal.
A In only three cases was it possible to achieve stable control on apomorphine without levodopa. This was not because apomorphine was weaker than levodopa but because the doses and therefore volumes of solution needed for monotherapy led to problems with skin nodules.
In general, apomorphine was well tolerated with relatively few side effects and no significant tolerance to the therapeutic antiparkinsonian effect was seen. On the other hand, tachyphylaxis to nausea and postural hypotension occurred rapidly. Reversible neuropsychiatric toxicity was uncommon. It may be that psychotoxic effects seen more frequently with other dopamine agonists occur as a result of different actions on dopamine receptor subtypes or other transmitter systems or perhaps apomorphine has intrinsic anti-psychotic activity,2' possibly from the piperidine moiety of the molecule.22
Intermittent injections may also be useful in treating a variety of isolated "off" period problems such as pain, dystonia, voiding dysfunction, anismus, hallucinosis, backache and belching."" '7 We consider some of these phenomena to be directly related to sustained levodopa therapy and not simply a return of former parkinsonian disability. Our experience with two patients with critical deterioration as a result of intercurrent illness suggests that there may be an emergency role for subcutaneous apomorphine including the management of the levodopa withdrawal syndrome which closely resembles the "neuroleptic malignant syndrome". Finally an apomorphine challenge, after domperidone pre-treatment, may prove to be a useful quick test for dopaminergic responsiveness.2'
These clinical observations using apomorphine may have some bearing on understanding the mechanism of the motor response to levodopa. The exact mode ofaction of levodopa is disputed but it has been suggested that presynaptic conversion to dopamine and intraneuronal storage are essential to its action.' Even if therapeutic responses to levodopa are not dependent on synaptic release of dopamine by surviving nigro-striatal terminals, these terminals are the major sites of dopamine formation from exogenous levodopa in the striatum.24 Apomorphine while possessing both D1 and D2 receptor agonist properties does not share transport or metabolic pathways with levodopa. Although in intact experimental animals, administration of apomorphine suppresses the rate of firing of nigro-striatal cells25 and in low dose has been found to produce a reduction in locomotor activity, thought to represent pre-synaptic inhibition of endogenous dopamine release, its actions on parkinsonian motor disability are likely to be mediated totally at post-synaptic receptor sites.
Comparison therefore of motor responses to levodopa and apomorphine may be relevant in trying to elucidate the mechanism of different degrees of levodopa responsiveness between individual parkinsonian patients. If impaired responsiveness is due to pre-synaptic changes in nigro-striatal terminals, differences in responsiveness to levodopa and apomorphine might be expected; whereas similarity in the pattern and magnitude of levodopa and apomorphine responses would suggest that differences in post-synaptic receptors cause differences in responsiveness. Our findings support the latter, but we have only looked at patients with prolonged disease duration who have either developed symptomatic motor oscillations or other problems during medium or long term treatment, we have not done comparative levodopa/apomorphine studies on untreated patients or those treated for a short time.
However, these considerations may still be of relevance to the practical long term management of parkinsonian patients with levodopa or dopamine agonist medication. If limitations in drug responsiveness are caused by striatal postsynaptic factors such as loss of receptor numbers or sensitivity, and motor responses to levodopa and apomorphine are equivalent in individual patients, it follows that the quality of "on" phase motor function on levodopa therapy is unlikely to be surpassed by other antiparkinsonian agents acting on the dopaminergic system. The maximum expected benefit from treatment with levodopa or dopamine agonist medication would be to maintain individual patients in "on" states for the greatest proportio.1 of the time. If the difference between "on" and "off' phase motor function is small, especially when the degree of disability is large, use of dopamine agonist therapy in conjunction with drug delivery technology (including subcutaneous delivery of apomorphine) or of surgical techniques to deliver levodopa or dopamine directly into the brain or CSF is unlikely to produce significant benefit.
Despite these reservations it seems likely that the duration of effective medical treatment can be significantly extended for many patients. These results also suggest that a search should continue for a long-acting powerful orally administered dopamine receptor agonist with a pharmacological profile similar to apomorphine. In the meantime the use of parenteral apomorphine provides an effective safe way of diminishing disabling "off" periods in levodopa treated patients.
